Denali Therapeutics Inc. Financing Cash Flow
Denali Therapeutics Inc. (DNLI) reported Financing Cash Flow of $234.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $14.98M, a 823.23% increase year-over-year.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $219.04M.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $192.13M.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$778.00K.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $189.22M, a 60.93% decline from fiscal 2024.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $484.30M, a 2617.76% increase from fiscal 2023.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $17.82M, a 94.26% decline from fiscal 2022.
- Denali Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $310.67M, a 1505.70% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $234.03M 10-Q · filed 2026-08-06 | $426.16M derived: sum of 3 quarters · filed 2026-08-06 | $425.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $219.04M 10-Q · filed 2026-05-07 | $411.18M derived: sum of 2 quarters · filed 2026-05-07 | $410.40M derived: sum of 3 quarters · filed 2026-05-07 | $412.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $192.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $191.35M derived: sum of 2 quarters · filed 2026-02-26 | $192.98M derived: sum of 3 quarters · filed 2026-08-06 | $189.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$778.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $845.00K derived: sum of 2 quarters · filed 2026-08-06 | -$2.92M 10-Q · filed 2025-11-06 | -$7.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.14M 10-Q · filed 2026-08-06 | -$6.31M derived: sum of 3 quarters · filed 2026-08-06 | -$24.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.76M 10-Q · filed 2026-05-07 | -$7.93M derived: sum of 2 quarters · filed 2026-05-07 | -$26.49M derived: sum of 3 quarters · filed 2026-05-07 | -$19.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$22.73M derived: sum of 2 quarters · filed 2026-02-26 | -$15.97M derived: sum of 3 quarters · filed 2026-02-26 | $484.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$18.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.80M derived: sum of 2 quarters · filed 2025-11-06 | $488.47M 10-Q · filed 2025-11-06 | $493.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $507.03M 10-Q · filed 2025-08-11 | $511.74M derived: sum of 3 quarters · filed 2026-02-26 | $514.23M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $500.27M 10-Q · filed 2025-05-06 | $504.98M derived: sum of 2 quarters · filed 2026-02-26 | $507.47M derived: sum of 3 quarters · filed 2026-02-26 | $516.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.20M derived: sum of 2 quarters · filed 2026-02-26 | $16.22M derived: sum of 3 quarters · filed 2026-02-26 | $17.82M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $11.51M derived: sum of 2 quarters · filed 2024-11-06 | $13.12M 10-Q · filed 2024-11-06 | $312.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $9.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $10.62M 10-Q · filed 2024-08-01 | $310.27M derived: sum of 3 quarters · filed 2025-02-27 | $315.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.60M 10-Q · filed 2024-05-07 | $301.25M derived: sum of 2 quarters · filed 2025-02-27 | $306.41M derived: sum of 3 quarters · filed 2025-02-27 | $310.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $299.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $304.81M derived: sum of 2 quarters · filed 2025-02-27 | $309.21M derived: sum of 3 quarters · filed 2025-02-27 | $310.67M 10-K · filed 2025-02-27 |
| 2022-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $9.56M derived: sum of 2 quarters · filed 2023-11-07 | $11.02M 10-Q · filed 2023-11-07 | $16.19M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.87M 10-Q · filed 2023-08-08 | $11.03M derived: sum of 3 quarters · filed 2024-02-28 | $14.35M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.46M 10-Q · filed 2023-05-08 | $6.63M derived: sum of 2 quarters · filed 2024-02-28 | $9.95M derived: sum of 3 quarters · filed 2024-02-28 | $16.99M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.48M derived: sum of 2 quarters · filed 2024-02-28 | $15.53M derived: sum of 3 quarters · filed 2024-02-28 | $19.35M 10-K · filed 2024-02-28 |
| 2021-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $10.36M derived: sum of 2 quarters · filed 2022-11-03 | $14.18M 10-Q · filed 2022-11-03 | $23.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $7.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $10.87M 10-Q · filed 2022-08-08 | $20.39M derived: sum of 3 quarters · filed 2023-02-27 | $446.29M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $3.82M 10-Q · filed 2022-05-05 | $13.34M derived: sum of 2 quarters · filed 2023-02-27 | $439.24M derived: sum of 3 quarters · filed 2023-02-27 | $442.66M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $435.42M derived: sum of 2 quarters · filed 2023-02-27 | $438.84M derived: sum of 3 quarters · filed 2023-02-27 | $634.75M 10-K · filed 2023-02-27 |
| 2020-09-30 | $425.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $429.31M derived: sum of 2 quarters · filed 2021-11-04 | $625.23M 10-Q · filed 2021-11-04 | $627.26M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $199.33M 10-Q · filed 2021-08-04 | $201.36M derived: sum of 3 quarters · filed 2022-02-28 | $202.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $195.91M 10-Q · filed 2021-05-05 | $197.95M derived: sum of 2 quarters · filed 2022-02-28 | $198.63M derived: sum of 3 quarters · filed 2022-02-28 | $201.19M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.71M derived: sum of 2 quarters · filed 2022-02-28 | $5.28M derived: sum of 3 quarters · filed 2022-02-28 | $6.19M 10-K · filed 2022-02-28 |
| 2019-09-30 | $679.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.25M derived: sum of 2 quarters · filed 2020-11-05 | $4.16M 10-Q · filed 2020-11-05 | $5.85M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $3.48M 10-Q · filed 2020-08-07 | $5.17M derived: sum of 3 quarters · filed 2021-02-26 | $5.83M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $908.00K 10-Q · filed 2020-05-07 | $2.60M derived: sum of 2 quarters · filed 2021-02-26 | $3.26M derived: sum of 3 quarters · filed 2021-02-26 | $4.69M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.35M derived: sum of 2 quarters · filed 2021-02-26 | $3.78M derived: sum of 3 quarters · filed 2021-02-26 | $97.02M 10-K · filed 2021-02-26 |
| 2018-09-30 | $658.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $2.09M derived: sum of 2 quarters · filed 2019-11-06 | $95.33M 10-Q · filed 2019-11-06 | $390.92M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $94.67M 10-Q · filed 2019-08-06 | $390.26M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | $93.24M 10-Q · filed 2019-05-08 | $388.83M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $295.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $296.32M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $732.00K 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $300.48M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |